MedPage Today) -- Patients with advanced non-progressing gastrointestinal stromal tumors (GIST) who discontinued imatinib had more rapid progression, faster development of resistance, and worse overall survival (OS), a small randomized trial showed...
.png)
 Copyright © 2023 googlenewsandentertainment. All Rights Reserved
